Sign inJoin waitlistJoin the waitlist

Brian Shuch

Urologic Oncology Fellowship Program Director · UCLA David Geffen School of Medicine/UCLA Medical Center

Credentials: · · · · ·

History

Urologic Oncology Fellowship · UCLA David Geffen School of Medicine/UCLA Medical Center
Present
focuses on decision Department · UCLA David Geffen School of Medicine/UCLA Medical Center
Present
UCLA David Geffen School of Medicine/UCLA Medical Center
Present

National Cancer Institute
2010–2013
Urology
UCLA David Geffen School of Medicine/UCLA Medical Center
2005–2010
General Surgery
University of California-Los Angeles
2004–2005
New York University Grossman School of Medicine
2000–2004

Research

Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma
New England Journal of Medicine · 2016 · 1,060 citations
The somatic genomic landscape of chromophobe renal cell carcinoma
Cancer Cell · 2014 · 675 citations
Epidemiology of Renal Cell Carcinoma: 2022 Update
Systematic review or meta-analysis · European Urology · 2022 · 648 citations

Arie Belldegrun
32 papers
Allan Pantuck
31 papers
Marston Linehan
30 papers
Toni Choueiri
21 papers
JS
Jamil Syed
18 papers · 18 as a resident
Jeffrey La Rochelle
17 papers · 5 as a resident
Adebowale Adeniran
15 papers
Eric Jonasch
15 papers
FK
Fairooz Kabbinavar
15 papers
Sumanta Pal
15 papers
Jonathan Said
14 papers
Srinivas Vourganti
14 papers · 11 as a resident

Grants

NCI Research Specialist/Clinician Scientist Award for Urologic Oncology Research
National Cancer Institute · R50
Contact PI · $459.8K · University of California Los Angeles
2023–2028
Genomic Heterogeneity and the Small Renal Mass
National Cancer Institute · K08
Contact PI · $682.2K · University of California Los Angeles
2016–2021

Clinical trials

Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer
Principal investigator · Not yet recruiting · Phase 1
Jonsson Comprehensive Cancer Center
2026–2035
An Investigational Scan (89Zr-DFO-GmAb PET/CT) Compared to Contrast-Enhanced CT for the Detection of Recurrent Clear Cell Renal Cell Cancer After Surgery Comparing Carbonic Anhydrase IX (CAIX) PET CT to Conventional PET CT for Post-Op Staging in Kidney Cancer
Principal investigator · Recruiting · Phase 2
Jonsson Comprehensive Cancer Center
2024–2030
Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer
Principal investigator · Withdrawn · Phase 2
Jonsson Comprehensive Cancer Center
2021–2023
SPECT/CT for the Characterization of Renal Masses
Principal investigator · Active not recruiting
Jonsson Comprehensive Cancer Center
2018–2027